Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 2 September 2024, 14:12 HKT/SGT
Share:
    

Source: Eisai
Eisai Announces Status Relating to Acquisition of Own Shares

Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. The status (progress report) of the acquisition is as described below.

1. Class of shares acquired: Ordinary shares of the Company
2. Total number of shares acquired: 1,598,800 shares
3. Aggregate amount of acquisition cost: JPY9,100,754,577
4. Acquisition period: From August 1 to August 31, 2024 (execution basis)
5. Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

For Reference

1. Resolution at a meeting of the Board of Directors held on May 15, 2024

(1) Class of shares to be acquired: Ordinary shares of the Company
(2) Total number of shares to be acquired: 6,500,000 shares (maximum)
(Ratio to total number of issued shares (excluding treasury shares): 2.3%)
(3) Total amount of acquisition cost: JPY30.0 billion (maximum)
(4) Period of acquisition: From May 16, 2024 to November 15, 2024
(5) Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

2. Accumulated number and price of own shares acquired in accordance with the above mentioned resolution at the meeting of Board of Directors (as of August 31, 2024)
(1) Total number of shares acquired: 4,037,300 shares
(2) Aggregate amount of acquisition cost: JPY24,933,137,242




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 5, 2024 15:59 HKT/SGT
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Aug 22, 2024 18:54 HKT/SGT
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Aug 14, 2024 08:59 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Aug 6, 2024 12:15 HKT/SGT
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
July 31, 2024 12:59 HKT/SGT
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
July 29, 2024 16:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
July 25, 2024 09:30 HKT/SGT
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
July 23, 2024 19:23 HKT/SGT
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
July 12, 2024 11:56 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 11, 2024 09:00 HKT/SGT
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: